Tamsulosin: The first prostate-selective α1A-adrenoceptor 1 antagonist for the treatment of symptomatic benign prostatic hyperplasia

Drugs of Today

Volumn 32, Issue 3, 1996, Pages 259-268

  Rabasseda, Xavier ^a   Fitzpatrick, John M ^b  

^a Medical Information Department   (Spain)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR; DOXAZOSIN; INDORAMIN; MORNIFLUMATE; PRAZOSIN; TAMSULOSIN; TERAZOSIN;

HEADACHE; HEART PALPITATION; HUMAN; HYPOTENSION; MOUSE; NOCTURIA; NONHUMAN; PROSTATE HYPERTROPHY; REVIEW; SEXUAL DYSFUNCTION; TACHYCARDIA; VERTIGO;

EID: 0029886182     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Chute, C.G., Panser, L.A., Girman, C.J., Oesterling, J.E., Guess, H.A., Jacobsen, S.J. et al. The prevalence of prostatism: A population-based survey of urinary symptoms. J Urol 1993, 150: 85-89.
2. Garraway, W.M., Collins, G.N., Lee, R.J. High prevalence of benign prostatic hypertrophy in the community. Lancet 1991, 338: 469-471.
3. Sagnier, P.P., MacFarlane, G., Richard, F., Botto, H., Teillac, P., Boyle, P. Results of an epidemiological survey using a modified American Urological Association symptom index for benign prostatic hyperplasia in France. J Urol 1994, 151: 1266-1270.
4. Denis, L.J. Quantification and incidence of benign prostatic hyperplasia. Drugs Today 1993, 29: 28-333.
5. Hieble, J.P., Caine, M., Zalaznik, E. In vitro characterization of the α-adrenoceptors in human prostate. Eur J Pharmacol 1985, 107: 111-117.
6. 1 adrenergic receptor subtypes in human prostate. J Urol 1993, 150: 546-551.
7. Lepor, H., Tang, R., Shapiro, E. The α-adrenoceptor subtype mediating the tension of human prostatic smooth muscle. The Prostate 1993, 22: 301-307.
8. 1-Adrenoceptor subtypes in the human prostate. Brit J Urol 1994, 74: 585-589.
9. 1c subtype. Mol Pharmacol 1994, 45: 703-708.
10. 1-adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery. Brit J Pharmacol 1994, 113: 723-728.
11. 1-adrenoceptor antagonists. J Pharm Pharmacol 1984, 36: 539-542.
12. 1-Adrenoceptor antagonist effects of the optical isomers of YM-12617 in rabbit lower urinary tract and prostate. J Pharmacol Exp Ther 1986, 239: 512-516.
13. 1-Adrenoceptor subtype mediating contraction of the smooth muscle in the lower urinary tract and prostate of rabbits. Naunyn Schmied Arch Pharmacol 1985, 330: 16-21.
14. 1A type. Jpn J Pharmacol 1993, 62: 297-304.
15. 1-adrenoceptor subtypes. Brit J Pharmacol 1995, 114 (Suppl.): 26P.
16. 1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy. Eur J Pharmacol 1995, 288: 201-207.
17. Breslin, D., Fields, D.W., Chou, T.C., Marion, D.M., Kane, M., Vaughan, E.D.J., Felsen, D. Medical management of benign prostatic hyperplasia: A canine model comparing the in vivo efficacy of α-1 adrenergic antagonists in the prostate. J Urol 1993, 149: 395-399.
18. Shibasaki, M., Sudoh, K., Inagaki, O., Uchida, W., Honda, K. Effect of the optical isomers of YM-12617 on increased intraurethral pressure induced by phenylephrine in anesthetized dogs. J Autonom Pharmacol 1992, 12: 263.
19. 1-adrenoceptor antagonist, on micturition reflexes and urethral pressure in anesthetized rats and dogs. Jpn J Pharmacol 1990, 52 (Suppl I): Abst O-178.
20. 1-blocker in the proximal urethral function using an in vivo model of isovolumetric pressure generation. 23rd Cong Soc Int Urol (18-22 Sept, Sydney) 1994, Abst 672.
21. 1-adrenoceptors. Naunyn Schmied Arch Pharmacol 1985, 328: 264-272.
22. 1-adrenergic receptor subtypes stably expressed in human embryonic kidney 293 cells: Antagonist potencies and sensitivity to inactivation by alkylating agents. Pharmacol Commun 1995, 5(2): 117-126.
23. 3H]prazosin binding sites. J Pharm Pharmacol 1989, 41: 714-716.
24. 1-adrenoceptors. Naunyn Schmied Arch Pharmacol 1993, 348: 385-395.
25. 1-adrenoceptor selectivity? Brit J Urol 1995, 76 (Suppl. 1): 47-55.
26. 1-adrenoceptor antagonist binding in human prostate and aorta. Clin Exp Pharmacol Physiol 1994, 21: 405-411.
27. 1-antagonist selective for the lower urinary tract: In vitro studies. Neurourol Urodyn 1994, 13: 473-474.
28. 1-adrenoceptor subtypes. Naunyn Schmied Arch Pharmacol 1994, 350: 136-142.
29. Watanabe, T., Fujiwara, M. Teratology study of orally administered amsulosin hydrochloride (YM617) in rats. Pharmacometrics 1991, 41: 31-37.
30. Itou, S., Fujiwara, M. Teratology study of orally administered amsulosin hydrochloride (YM617) in rabbits. Pharmacometrics 1991, 41: 39-42.
31. 1-adrenoceptor antagonist, inhibits fertility of male rats. Andrologia 1994, 26: 107-110.
32. Ratnasooriya, W.D., Ananda, U.V.D.S., Ratnasooriya, C.P. The effect of terazosin, a selective α-adrenoceptor antagonist, on the fertility of male rats. Med Sci Res 1992, 20: 133-135.
33. Ratnasooriya, W.D., Wadsworth, R.M. Impairment of fertility of male rats with prazosin. Contraception 1990, 41: 441-447.
34. 14C-amsulosin hydrochloride in rats and dogs. Pharmacometrics 1990, 40: 101-109.
35. Blum, R.A., Kamimura, H., Higuchi, S., Ochiai, H., Schentag, J.J. Pharmacokinetics of YM617 in subjects with renal insufficiency. Clin Pharmacol Ther 1995, 57: 218.
36. Blum, R.A., Kamimura, H., Higuchi, S., Ochiai, H., Schentag, J.J. Pharmacokinetics of YM617 in subjects with hepatic insufficiency. Clin Pharmacol Ther 1995, 57: 149.
37. Starkey, L.P., Yasukawa, K., Trenga, C., Miyazawa, Y, Ito, Y. Study of possible pharmacodynamic interaction between tamsulosin and nifedipine in subjects with essential hypertension. J Clin Pharmacol 1994, 34: 1019.
38. Starkey, L.P., Trenga, C., Mryazawa, Y., Ito, Y. Lack of clinical interaction effects between tamsulosin and enalapril. Clin Pharmacol Ther 1995, 57: 166.
39. Kimisawa, Y. Effect of an adrenergic α-blocker in prostate enlargement and bladder induration. Jpn J Ural 1985, 76: 1740.
40. 1-blocker, YM-12617, in micturition difficulty. Ural Int 1987, 42: 280-284.
41. 1-blocker, YM617, in the treatment of benign prostatic hypertrophy. J Urol 1990, 144: 908-911.
42. 1c-adrenoceptor antagonist: A randomized controlled trial in patients with benign prostatic "obstruction" (symptomatic BPH). Brit J Urol 1995, 76: 325-336.
43. 1c antagonist. J Urol 1995, 153 (Suppl.): 274A.
44. 1A-adrenoceptor antagonist: A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). Eur Urol 1996. 29: 155-167.
45. 1A-zdrenoceptor antagonist: An interim analysis of a multinational, multicentre, open-label study assessing the long-term efficacy and safety in patients with benign prostatic obstruction (symptomatic BPH). Eur Urol 1996, 29: 145-154.
46. Hayashida, S., Hirasawa, T., Uchiyama, K., Shinohara, Y., Mitui, H., Nasu, T. Effect of tamsulosin hydrochloride on benign prostatic hyperplasia: Comparison with prazosin hydrochloride. 23rd Cong Soc Int Urol (18-22 Sept, Sydney) 1994, Abst 93.
47. Roehrborn, C.G. The newly established guidelines for the diagnosis and management of benign prostatic hyperplasia. Curr Opin Urol 1995, 5: 30-34.
48. Jiménez Cruz, J.F. The role of α-adrenergic blockers in the treatment of prostatic hypertrophy. Drugs Today 1993, 29: 343-349.
49. 1-adrenoceptors: Consensus update. Pharmacol Rev 1995, 47: 267-270.
50. 1995 Receptor & Ion Channel Nomenclature Supplement. Trends Pharmacol Sci 1995, Suppl.